A certain class of diabetes drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors may help reduce the risk of dementia and Parkinson's disease, a recent study revealed.
SGLT2, also known as gliflozins, works by reducing blood sugar levels by helping the kidneys remove sugar from the body through urine. In the latest study published in the journal Neurology, researchers noted that the use of these drugs was associated with a 20% reduced risk of Alzheimer's disease, a 20% reduced risk of Parkinson's disease, and a 30% reduced risk of developing vascular dementia after adjusting for other factors.
